57.23 USD
↗ 0.07 (0.11%)PRE MARKET (AS OF 08:36 AM EDT)
Royalty Pharma plc Class A Ordinary Shares
RPRXNASDAQ • USD
Market: OPEN
Royalty Pharma plc Class A Ordinary Shares (RPRX) is currently trading at $57.23. Technicals currently rate "Strong Sell" while our fundamental analysis reads "Neutral". Notable factors include a bullish Golden Cross on the moving averages. Valuation metrics place RPRX at a fair price relative to peers.
Technical & fundamental data as of Oct 2, 2026.
Open?$57.96
High?$57.96
Low?$57.23
Prev. Close?$57.16
Volume?658
Avg. Volume?3.0M
VWAP?$57.24
Rel. Volume?0.00x
Bid / Ask
Bid?$54.31 × 100
Ask?$60.16 × 100
Spread?$5.85
Midpoint?$57.24
Valuation & Ratios
Market Cap?25.5B
Shares Out?445.3M
Float?435.9M
Float %?98.3%
P/E Ratio?31.23
P/B Ratio?3.73
EPS?$1.83
Dividend?1.57%
Ex-Dividend?N/A
News
Profile
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Themes
Employees
100
Market Cap
25.5B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2020-06-16
Address
110 EAST 59TH STREET
NEW YORK, NY 10022
Phone: (212) 883-0200
NEW YORK, NY 10022
Phone: (212) 883-0200
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-1/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?40
Z-Score?41
Momentum?73
Short Sent.?78
Piotroski F-Score?4/9Mixed
Altman Z-Score?2.14Grey
Confidence?74%Moderate
Short InterestModerate
Short % of Float?2.67%Low
Short Interest?11.6M
Days to Cover?3.3
Free Float435.9M
Avg Daily Volume3.6M
Settlement Date2026-09-15
Financial Health
Current Ratio?2.80Strong
Quick Ratio?2.80Strong
Cash Ratio?1.29Strong
Debt/Equity?1.33Moderate
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score56/100
P/E?31.2PRICEY▾
Peers100
S&P30
P/B?3.73FAIR▾
Peers100
S&P47
P/S?10.04HIGH▾
Peers100
S&P8
P/FCF?8.6CHEAP▾
Peers100
S&P92
EV/EBITDA?19.7FAIR▾
Peers100
S&P27
EV/Sales?13.29HIGH▾
Peers100
S&P6
Returns & Efficiency
ROE?11.9%FAIR▾
Peers50
S&P43
ROA?4.1%FAIR▾
Peers50
S&P37
Cash Flow & Enterprise
FCF?$3.0B
Enterprise Value?$33.7B
Fundamentals ratios updated end of day